Market Outlook
The global PD-L1 Biomarker Testing market size was valued at USD 1513.1 million in 2022 and is forecast to a readjusted size of USD 13730 million by 2029 with a CAGR of 37.0% during review period.
PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances. Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).
PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies. PDL1 testing is used to find out if you have a cancer that may benefit from immunotherapy.
The classification of PD-L1 Biomarker Testing includes PD-L1 (22C3), PD-L1 (28-8), PD-L1 (SP142), PD-L1 (SP263) and Other, and the revenue proportion of PD-L1 (22C3) in 2019 is about 21.68%. PD-L1 Biomarker Testing is widely used in Hospital and Diagnostic Laboratories. The most proportion of PD-L1 Biomarker Testing is Hospital, and the proportion in 2019 is about 52.7%. North Americas is the largest consumption place, with a consumption market share nearly 55.63% in 2019. Following North Americas, Europe is the second largest consumption place with the consumption market share of 26.7%.
This report is a detailed and comprehensive analysis for global PD-L1 Biomarker Testing market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global PD-L1 Biomarker Testing market size and forecasts, in consumption value ($ Million), 2018-2029
Global PD-L1 Biomarker Testing market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global PD-L1 Biomarker Testing market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global PD-L1 Biomarker Testing market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for PD-L1 Biomarker Testing
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global PD-L1 Biomarker Testing market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Key Market Players
Agilent Technologies
Roche
Merck
Bristol-Myers Squibb
AstraZeneca
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
Segmentation By Type
PD-L1 (22C3)
PD-L1(28-8)
PD-L1 (SP142)
PD-L1 (SP263)
Other
Segmentation By Application
Hospital
Diagnostic Center
Others
Segmentation By Region
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Market SWOT Analysis
What are the strengths of the PD-L1 biomarker testing market in 2025?
The PD-L1 biomarker testing market in 2025 benefits from the growing adoption of immunotherapy in cancer treatment. These tests are crucial for identifying patients who will respond well to immune checkpoint inhibitors, improving personalized treatment approaches. Technological advancements and a rise in early cancer detection methods further enhance the market's strength. Additionally, increased healthcare awareness and funding for cancer research contribute to its growth.
What are the weaknesses of the PD-L1 biomarker testing market in 2025?
A significant weakness lies in the lack of standardized testing procedures across various laboratories, leading to inconsistent results. High testing costs and limited access to advanced diagnostic tools in emerging markets may also hinder widespread adoption. Moreover, some healthcare systems may struggle with integrating biomarker testing into routine clinical practice due to limited reimbursement policies.
What are the opportunities for the PD-L1 biomarker testing market in 2025?
Opportunities include expanding research into new cancers beyond non-small cell lung cancer (NSCLC), as PD-L1 testing could be applicable in a broader range of malignancies. The increasing demand for precision medicine and the growth of biopharmaceutical companies developing PD-L1 inhibitors offer a chance for market expansion. Collaboration between diagnostic firms and pharmaceutical companies also opens doors for innovation in test development.
What are the threats to the PD-L1 biomarker testing market in 2025?
Threats to the market include potential regulatory hurdles as testing methods evolve and as more studies are conducted to validate the clinical relevance of PD-L1 as a biomarker. The emergence of alternative biomarkers and competing diagnostic technologies could also pose challenges. Additionally, healthcare budget constraints and potential delays in approval processes may slow down market growth.
Market PESTEL Analysis
What are the political factors influencing the PD-L1 biomarker testing market in 2025?
Political factors include government regulations on healthcare spending, especially in relation to cancer treatment and diagnostics. Policy decisions around funding for cancer research and the approval of new diagnostic technologies will impact the market. Additionally, healthcare reforms and reimbursement policies can either facilitate or hinder the adoption of PD-L1 biomarker testing across different regions.
What are the economic factors impacting the PD-L1 biomarker testing market in 2025?
Economic factors such as the overall healthcare budget, the affordability of PD-L1 testing, and the financial capacity of both public and private healthcare providers play a significant role. In high-income countries, the market is more likely to expand due to higher reimbursement rates and better access to cutting-edge technologies. Conversely, in low- and middle-income countries, economic barriers could slow down adoption and growth.
What are the social factors affecting the PD-L1 biomarker testing market in 2025?
Social factors include the increasing awareness and demand for personalized medicine and cancer immunotherapies. Patients' growing interest in precision medicine, as well as the rising prevalence of cancer, will drive demand for biomarker testing. However, disparities in healthcare access, particularly in underserved populations, may limit the widespread social acceptance and use of PD-L1 biomarker testing.
What are the technological factors influencing the PD-L1 biomarker testing market in 2025?
Technological advancements in diagnostic tools and artificial intelligence for better test accuracy and efficiency will positively influence the market. The development of companion diagnostics that can integrate PD-L1 testing with immunotherapy drugs will be a key growth factor. On the flip side, the rapid pace of technological change may present challenges in standardizing tests and ensuring regulatory compliance.
What are the environmental factors affecting the PD-L1 biomarker testing market in 2025?
Environmental factors are less directly impactful on the PD-L1 biomarker testing market, but the sustainability of the healthcare system and environmental regulations on manufacturing and waste management in diagnostic equipment can play a role. A shift toward greener and more sustainable practices in the production and disposal of diagnostic tools may increase costs but could benefit long-term market stability.
What are the legal factors that could impact the PD-L1 biomarker testing market in 2025?
Legal factors include intellectual property laws around the development of PD-L1 testing technologies, as well as the regulatory frameworks for approval and commercialization. Legal challenges regarding patent rights, data privacy for patient samples, and malpractice claims in diagnostic testing could pose risks. Additionally, varying regulations for medical devices across countries can complicate market entry for new technologies.
Market SIPOC Analysis
What are the suppliers in the PD-L1 biomarker testing market in 2025?
Suppliers in this market include pharmaceutical companies that develop PD-L1 inhibitors, diagnostic test manufacturers, and providers of laboratory equipment. Additionally, reagent suppliers and biotechnology companies that create assay kits or diagnostic platforms play a key role. Suppliers also include research organizations that advance the scientific understanding of biomarkers and immunotherapy.
What are the inputs in the PD-L1 biomarker testing market in 2025?
Inputs involve the PD-L1 testing kits, laboratory reagents, and diagnostic platforms that are used for sample analysis. These also include trained medical professionals, patient samples, and the necessary technologies for conducting genetic analysis and immunohistochemistry tests. Research and clinical data for validating the tests are also critical inputs.
What are the processes involved in the PD-L1 biomarker testing market in 2025?
The processes include sample collection, patient diagnosis, testing (using technologies like immunohistochemistry, PCR, or next-generation sequencing), result analysis, and reporting. These processes are followed by the clinical interpretation of the results to determine patient eligibility for specific immunotherapies. Continuous quality control and standardization of testing procedures are also integral parts of the process.
What are the outputs of the PD-L1 biomarker testing market in 2025?
The outputs of this market include accurate PD-L1 biomarker test results, which are used to guide treatment decisions in cancer care. These outputs directly impact the choice of immunotherapy for patients, particularly in cancers like non-small cell lung cancer. Additionally, the output extends to improved patient outcomes due to personalized treatment approaches.
What are the customers in the PD-L1 biomarker testing market in 2025?
Customers include oncologists, hospitals, diagnostic labs, pharmaceutical companies, and healthcare providers who rely on PD-L1 testing to guide therapeutic decisions. Patients seeking personalized treatment options for cancer are also key indirect customers. Furthermore, regulatory bodies and healthcare insurance providers are customers in terms of policy formulation and reimbursement decisions related to biomarker testing.
Market Porter's Five Forces
What is the threat of new entrants in the PD-L1 biomarker testing market in 2025?
The threat of new entrants is moderate. While the market offers growth opportunities due to the rising demand for personalized cancer treatment, the high capital investment required for advanced diagnostic technologies, stringent regulatory hurdles, and the need for specialized expertise act as barriers to entry. Established players with strong intellectual property and brand recognition dominate the market, making it difficult for new entrants to compete effectively.
What is the bargaining power of suppliers in the PD-L1 biomarker testing market in 2025?
The bargaining power of suppliers is moderate to high. Suppliers of key components like diagnostic reagents, laboratory equipment, and biomarker testing kits hold significant power due to the specialized nature of the products. There are few suppliers who provide highly standardized and validated test kits, and any supply chain disruptions could impact the availability of testing materials. However, the growing number of biotech companies entering the market may offer more options to buyers in the future.
What is the bargaining power of buyers in the PD-L1 biomarker testing market in 2025?
The bargaining power of buyers is relatively low. Hospitals, diagnostic labs, and oncologists typically do not have the luxury of negotiating prices due to the specialized and critical nature of PD-L1 biomarker testing. These tests are essential for making informed decisions about immunotherapy treatments, which means buyers are less likely to switch to alternative solutions based solely on price. However, larger healthcare networks or insurance providers may have more negotiating power.
What is the threat of substitute products or services in the PD-L1 biomarker testing market in 2025?
The threat of substitutes is moderate. While alternative biomarkers or diagnostic technologies (e.g., tumor mutational burden or other immune-related markers) could potentially provide similar clinical insights, PD-L1 testing remains one of the most widely used methods for determining patient eligibility for specific immunotherapies. However, as research advances, new biomarkers or improved diagnostic platforms could emerge, posing a potential substitute threat in the future.
What is the intensity of competitive rivalry in the PD-L1 biomarker testing market in 2025?
The intensity of competitive rivalry is high. The market is characterized by strong competition among established players, including diagnostic companies, pharmaceutical companies, and biotech firms that specialize in biomarker testing. Companies are constantly innovating, seeking to improve the accuracy, speed, and cost-efficiency of their tests. Additionally, the presence of large pharmaceutical companies that are investing in companion diagnostics to complement their immunotherapies further intensifies the competitive landscape.
Market Upstream Analysis
What are the key raw materials and inputs in the PD-L1 biomarker testing market in 2025?
Key inputs include diagnostic reagents, antibodies, and assay kits used for the detection of PD-L1 expression in patient samples. High-quality laboratory equipment, including microscopes, sequencing platforms, and imaging systems, is also crucial. Additionally, research data on biomarkers and access to patient samples for clinical testing are essential raw materials that fuel the development of new diagnostic technologies.
What are the critical suppliers for the PD-L1 biomarker testing market in 2025?
Critical suppliers include biotechnology and pharmaceutical companies that manufacture antibodies and reagents for biomarker testing. Diagnostic equipment manufacturers provide the necessary instruments for testing and analysis. Suppliers of laboratory consumables, such as slides, staining kits, and tissue samples, are also integral. Furthermore, data analytics and software companies that offer solutions for interpreting PD-L1 test results contribute to the upstream supply chain.
What are the technological drivers shaping the PD-L1 biomarker testing market in 2025?
Technological advancements such as next-generation sequencing (NGS) and digital pathology are transforming the PD-L1 biomarker testing market. Improved high-throughput platforms and artificial intelligence tools for result interpretation are also critical enablers. The integration of these technologies with companion diagnostics to personalize cancer treatments is a key technological driver in the upstream supply chain.
What are the regulatory and compliance requirements impacting the upstream supply chain in 2025?
The upstream supply chain is impacted by regulatory requirements set by authorities such as the FDA, EMA, and other national agencies. These include stringent standards for biomarker testing kits, reagents, and diagnostic devices. Suppliers must adhere to Good Manufacturing Practices (GMP) and undergo regular inspections and validations. Moreover, intellectual property protection and patent laws around diagnostic innovations also play a significant role in shaping the upstream dynamics.
What are the key challenges faced by suppliers in the PD-L1 biomarker testing market in 2025?
Suppliers face challenges such as the high cost of research and development for advanced diagnostic tools, along with the need to meet evolving regulatory standards. There is also the issue of ensuring a steady supply of high-quality raw materials and reagents, which can be scarce or expensive. Additionally, the complexity of developing tests that are both accurate and widely applicable across different cancer types presents a significant hurdle.
Market Midstream Analysis
What are the key processes in the midstream of the PD-L1 biomarker testing market in 2025?
The key processes in the midstream include the transportation, handling, and storage of diagnostic reagents, test kits, and patient samples. Clinical laboratories perform the PD-L1 testing by using established platforms such as immunohistochemistry (IHC) or next-generation sequencing (NGS). The data generated from these tests is then analyzed and interpreted to guide therapeutic decisions for patients. The entire process must adhere to stringent quality control standards to ensure reliable results.
What role do diagnostic laboratories play in the midstream of the PD-L1 biomarker testing market in 2025?
Diagnostic laboratories are central to the midstream process. They conduct the actual testing, which includes sample preparation, analysis, and result interpretation. Laboratories may offer specialized testing for different types of cancers, and they play a key role in ensuring the accuracy and reliability of the test results. Additionally, these labs are involved in implementing new testing methodologies as the market evolves.
What are the key players in the midstream supply chain for the PD-L1 biomarker testing market in 2025?
Key players in the midstream include independent diagnostic laboratories, hospital-based labs, and specialized clinical testing centers. These players collaborate with pharmaceutical companies, test kit manufacturers, and healthcare providers to deliver PD-L1 biomarker testing services. Additionally, organizations that provide data management and analysis tools, often powered by artificial intelligence, contribute to the midstream value chain by aiding in test result interpretation.
What are the challenges faced in the midstream of the PD-L1 biomarker testing market in 2025?
Challenges in the midstream include ensuring the consistency and quality of test results across different laboratories due to variations in technology and techniques. Maintaining the integrity of patient samples during transport and storage is another significant challenge. Additionally, the high complexity of PD-L1 testing, especially with newer methods like NGS, can result in longer turnaround times and increased costs, creating pressure on labs to optimize workflows and reduce errors.
What opportunities exist in the midstream of the PD-L1 biomarker testing market in 2025?
Opportunities in the midstream include advancements in automation and digitalization of lab processes, which could improve testing efficiency and accuracy. The growing demand for personalized cancer therapies presents an opportunity for labs to offer more specialized, high throughput testing services. Collaborations with pharmaceutical companies to offer companion diagnostic services for immunotherapy treatments could further expand the market for PD-L1 biomarker testing. Additionally, integrating AI-driven analytics for faster, more reliable result interpretation offers another growth avenue.
Market Downstream Analysis
What are the key activities in the downstream of the PD-L1 biomarker testing market in 2025?
Key activities in the downstream involve the distribution of PD-L1 test results to oncologists, clinicians, and healthcare providers who use the data to guide personalized cancer treatments. These results help determine which patients are eligible for immunotherapy, influencing treatment decisions and patient care strategies. Additionally, pharmaceutical companies may use these results for clinical trials and drug development.
What role do healthcare providers play in the downstream of the PD-L1 biomarker testing market in 2025?
Healthcare providers, including oncologists and treatment centers, are crucial in the downstream process. They utilize PD-L1 test results to make informed decisions about prescribing immune checkpoint inhibitors and other personalized cancer therapies. These providers also collaborate with diagnostic laboratories to ensure timely testing and facilitate patient access to cutting-edge treatments based on biomarker results.
What are the key challenges faced in the downstream of the PD-L1 biomarker testing market in 2025?
Challenges in the downstream include delays in receiving test results, which can delay treatment initiation. There may also be variability in the interpretation of results, leading to inconsistent treatment decisions. Furthermore, limited reimbursement and access to testing in certain regions, especially in low-income countries, can hinder the adoption of PD-L1 biomarker testing in clinical practice.
What are the opportunities in the downstream of the PD-L1 biomarker testing market in 2025?
Opportunities in the downstream include the growing trend of precision medicine, which increases demand for biomarker-driven treatment decisions. The integration of PD-L1 testing into routine clinical practice offers a chance to improve patient outcomes and optimize treatment regimens. Additionally, partnerships between pharmaceutical companies and healthcare providers can lead to better access to immunotherapy and more personalized care options for patients.
What impact do insurance and reimbursement policies have on the downstream of the PD-L1 biomarker testing market in 2025?
Insurance and reimbursement policies significantly affect the downstream market by determining how accessible PD-L1 biomarker testing is for patients. Favorable reimbursement policies can make testing more affordable and widely adopted, encouraging healthcare providers to use it more frequently in clinical decision-making. However, if reimbursement is limited or inconsistent, patients may face barriers to receiving timely and essential testing, ultimately impacting treatment outcomes.
Chapter 1, to describe PD-L1 Biomarker Testing product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of PD-L1 Biomarker Testing, with revenue, gross margin and global market share of PD-L1 Biomarker Testing from 2018 to 2023.
Chapter 3, the PD-L1 Biomarker Testing competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and PD-L1 Biomarker Testing market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of PD-L1 Biomarker Testing.
Chapter 13, to describe PD-L1 Biomarker Testing research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of PD-L1 Biomarker Testing
1.2 Market Estimation Caveats and Base Year
1.3 Classification of PD-L1 Biomarker Testing by Type
1.3.1 Overview: Global PD-L1 Biomarker Testing Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global PD-L1 Biomarker Testing Consumption Value Market Share by Type in 2022
1.3.3 PD-L1 (22C3)
1.3.4 PD-L1(28-8)
1.3.5 PD-L1 (SP142)
1.3.6 PD-L1 (SP263)
1.3.7 Other
1.4 Global PD-L1 Biomarker Testing Market by Application
1.4.1 Overview: Global PD-L1 Biomarker Testing Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Diagnostic Center
1.4.4 Others
1.5 Global PD-L1 Biomarker Testing Market Size & Forecast
1.6 Global PD-L1 Biomarker Testing Market Size and Forecast by Region
1.6.1 Global PD-L1 Biomarker Testing Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global PD-L1 Biomarker Testing Market Size by Region, (2018-2029)
1.6.3 North America PD-L1 Biomarker Testing Market Size and Prospect (2018-2029)
1.6.4 Europe PD-L1 Biomarker Testing Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific PD-L1 Biomarker Testing Market Size and Prospect (2018-2029)
1.6.6 South America PD-L1 Biomarker Testing Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa PD-L1 Biomarker Testing Market Size and Prospect (2018-2029)
2 Company Profiles
2.1 Agilent Technologies
2.1.1 Agilent Technologies Details
2.1.2 Agilent Technologies Major Business
2.1.3 Agilent Technologies PD-L1 Biomarker Testing Product and Solutions
2.1.4 Agilent Technologies PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Agilent Technologies Recent Developments and Future Plans
2.2 Roche
2.2.1 Roche Details
2.2.2 Roche Major Business
2.2.3 Roche PD-L1 Biomarker Testing Product and Solutions
2.2.4 Roche PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Roche Recent Developments and Future Plans
2.3 Merck
2.3.1 Merck Details
2.3.2 Merck Major Business
2.3.3 Merck PD-L1 Biomarker Testing Product and Solutions
2.3.4 Merck PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Merck Recent Developments and Future Plans
2.4 Bristol-Myers Squibb
2.4.1 Bristol-Myers Squibb Details
2.4.2 Bristol-Myers Squibb Major Business
2.4.3 Bristol-Myers Squibb PD-L1 Biomarker Testing Product and Solutions
2.4.4 Bristol-Myers Squibb PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.5 AstraZeneca
2.5.1 AstraZeneca Details
2.5.2 AstraZeneca Major Business
2.5.3 AstraZeneca PD-L1 Biomarker Testing Product and Solutions
2.5.4 AstraZeneca PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 AstraZeneca Recent Developments and Future Plans
2.6 Ono Pharmaceutical
2.6.1 Ono Pharmaceutical Details
2.6.2 Ono Pharmaceutical Major Business
2.6.3 Ono Pharmaceutical PD-L1 Biomarker Testing Product and Solutions
2.6.4 Ono Pharmaceutical PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Ono Pharmaceutical Recent Developments and Future Plans
2.7 Regeneron
2.7.1 Regeneron Details
2.7.2 Regeneron Major Business
2.7.3 Regeneron PD-L1 Biomarker Testing Product and Solutions
2.7.4 Regeneron PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Regeneron Recent Developments and Future Plans
2.8 Innovent
2.8.1 Innovent Details
2.8.2 Innovent Major Business
2.8.3 Innovent PD-L1 Biomarker Testing Product and Solutions
2.8.4 Innovent PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Innovent Recent Developments and Future Plans
2.9 Hengrui Medicine
2.9.1 Hengrui Medicine Details
2.9.2 Hengrui Medicine Major Business
2.9.3 Hengrui Medicine PD-L1 Biomarker Testing Product and Solutions
2.9.4 Hengrui Medicine PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Hengrui Medicine Recent Developments and Future Plans
2.10 Junshi Biosciences
2.10.1 Junshi Biosciences Details
2.10.2 Junshi Biosciences Major Business
2.10.3 Junshi Biosciences PD-L1 Biomarker Testing Product and Solutions
2.10.4 Junshi Biosciences PD-L1 Biomarker Testing Revenue, Gross Margin and Market Share (2018-2023)
2.10.5 Junshi Biosciences Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global PD-L1 Biomarker Testing Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of PD-L1 Biomarker Testing by Company Revenue
3.2.2 Top 3 PD-L1 Biomarker Testing Players Market Share in 2022
3.2.3 Top 6 PD-L1 Biomarker Testing Players Market Share in 2022
3.3 PD-L1 Biomarker Testing Market: Overall Company Footprint Analysis
3.3.1 PD-L1 Biomarker Testing Market: Region Footprint
3.3.2 PD-L1 Biomarker Testing Market: Company Product Type Footprint
3.3.3 PD-L1 Biomarker Testing Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
4.1 Global PD-L1 Biomarker Testing Consumption Value and Market Share by Type (2018-2023)
4.2 Global PD-L1 Biomarker Testing Market Forecast by Type (2024-2029)
5 Market Size Segment by Application
5.1 Global PD-L1 Biomarker Testing Consumption Value Market Share by Application (2018-2023)
5.2 Global PD-L1 Biomarker Testing Market Forecast by Application (2024-2029)
6 North America
6.1 North America PD-L1 Biomarker Testing Consumption Value by Type (2018-2029)
6.2 North America PD-L1 Biomarker Testing Consumption Value by Application (2018-2029)
6.3 North America PD-L1 Biomarker Testing Market Size by Country
6.3.1 North America PD-L1 Biomarker Testing Consumption Value by Country (2018-2029)
6.3.2 United States PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
6.3.3 Canada PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
6.3.4 Mexico PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
7 Europe
7.1 Europe PD-L1 Biomarker Testing Consumption Value by Type (2018-2029)
7.2 Europe PD-L1 Biomarker Testing Consumption Value by Application (2018-2029)
7.3 Europe PD-L1 Biomarker Testing Market Size by Country
7.3.1 Europe PD-L1 Biomarker Testing Consumption Value by Country (2018-2029)
7.3.2 Germany PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
7.3.3 France PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
7.3.4 United Kingdom PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
7.3.5 Russia PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
7.3.6 Italy PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
8 Asia-Pacific
8.1 Asia-Pacific PD-L1 Biomarker Testing Consumption Value by Type (2018-2029)
8.2 Asia-Pacific PD-L1 Biomarker Testing Consumption Value by Application (2018-2029)
8.3 Asia-Pacific PD-L1 Biomarker Testing Market Size by Region
8.3.1 Asia-Pacific PD-L1 Biomarker Testing Consumption Value by Region (2018-2029)
8.3.2 China PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
8.3.3 Japan PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
8.3.4 South Korea PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
8.3.5 India PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
8.3.7 Australia PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
9 South America
9.1 South America PD-L1 Biomarker Testing Consumption Value by Type (2018-2029)
9.2 South America PD-L1 Biomarker Testing Consumption Value by Application (2018-2029)
9.3 South America PD-L1 Biomarker Testing Market Size by Country
9.3.1 South America PD-L1 Biomarker Testing Consumption Value by Country (2018-2029)
9.3.2 Brazil PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
9.3.3 Argentina PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
10 Middle East & Africa
10.1 Middle East & Africa PD-L1 Biomarker Testing Consumption Value by Type (2018-2029)
10.2 Middle East & Africa PD-L1 Biomarker Testing Consumption Value by Application (2018-2029)
10.3 Middle East & Africa PD-L1 Biomarker Testing Market Size by Country
10.3.1 Middle East & Africa PD-L1 Biomarker Testing Consumption Value by Country (2018-2029)
10.3.2 Turkey PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
10.3.4 UAE PD-L1 Biomarker Testing Market Size and Forecast (2018-2029)
11 Market Dynamics
11.1 PD-L1 Biomarker Testing Market Drivers
11.2 PD-L1 Biomarker Testing Market Restraints
11.3 PD-L1 Biomarker Testing Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
11.5 Influence of COVID-19 and Russia-Ukraine War
11.5.1 Influence of COVID-19
11.5.2 Influence of Russia-Ukraine War
12 Industry Chain Analysis
12.1 PD-L1 Biomarker Testing Industry Chain
12.2 PD-L1 Biomarker Testing Upstream Analysis
12.3 PD-L1 Biomarker Testing Midstream Analysis
12.4 PD-L1 Biomarker Testing Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
List of Tables
Table 1. Global PD-L1 Biomarker Testing Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global PD-L1 Biomarker Testing Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global PD-L1 Biomarker Testing Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global PD-L1 Biomarker Testing Consumption Value by Region (2024-2029) & (USD Million)
Table 5. Agilent Technologies Company Information, Head Office, and Major Competitors
Table 6. Agilent Technologies Major Business
Table 7. Agilent Technologies PD-L1 Biomarker Testing Product and Solutions
Table 8. Agilent Technologies PD-L1 Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. Agilent Technologies Recent Developments and Future Plans
Table 10. Roche Company Information, Head Office, and Major Competitors
Table 11. Roche Major Business
Table 12. Roche PD-L1 Biomarker Testing Product and Solutions
Table 13. Roche PD-L1 Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Roche Recent Developments and Future Plans
Table 15. Merck Company Information, Head Office, and Major Competitors
Table 16. Merck Major Business
Table 17. Merck PD-L1 Biomarker Testing Product and Solutions
Table 18. Merck PD-L1 Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Merck Recent Developments and Future Plans
Table 20. Bristol-Myers Squibb Company Information, Head Office, and Major Competitors
Table 21. Bristol-Myers Squibb Major Business
Table 22. Bristol-Myers Squibb PD-L1 Biomarker Testing Product and Solutions
Table 23. Bristol-Myers Squibb PD-L1 Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Bristol-Myers Squibb Recent Developments and Future Plans
Table 25. AstraZeneca Company Information, Head Office, and Major Competitors
Table 26. AstraZeneca Major Business
Table 27. AstraZeneca PD-L1 Biomarker Testing Product and Solutions
Table 28. AstraZeneca PD-L1 Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. AstraZeneca Recent Developments and Future Plans
Table 30. Ono Pharmaceutical Company Information, Head Office, and Major Competitors
Table 31. Ono Pharmaceutical Major Business
Table 32. Ono Pharmaceutical PD-L1 Biomarker Testing Product and Solutions
Table 33. Ono Pharmaceutical PD-L1 Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Ono Pharmaceutical Recent Developments and Future Plans
Table 35. Regeneron Company Information, Head Office, and Major Competitors
Table 36. Regeneron Major Business
Table 37. Regeneron PD-L1 Biomarker Testing Product and Solutions
Table 38. Regeneron PD-L1 Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Regeneron Recent Developments and Future Plans
Table 40. Innovent Company Information, Head Office, and Major Competitors
Table 41. Innovent Major Business
Table 42. Innovent PD-L1 Biomarker Testing Product and Solutions
Table 43. Innovent PD-L1 Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Innovent Recent Developments and Future Plans
Table 45. Hengrui Medicine Company Information, Head Office, and Major Competitors
Table 46. Hengrui Medicine Major Business
Table 47. Hengrui Medicine PD-L1 Biomarker Testing Product and Solutions
Table 48. Hengrui Medicine PD-L1 Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Hengrui Medicine Recent Developments and Future Plans
Table 50. Junshi Biosciences Company Information, Head Office, and Major Competitors
Table 51. Junshi Biosciences Major Business
Table 52. Junshi Biosciences PD-L1 Biomarker Testing Product and Solutions
Table 53. Junshi Biosciences PD-L1 Biomarker Testing Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 54. Junshi Biosciences Recent Developments and Future Plans
Table 55. Global PD-L1 Biomarker Testing Revenue (USD Million) by Players (2018-2023)
Table 56. Global PD-L1 Biomarker Testing Revenue Share by Players (2018-2023)
Table 57. Breakdown of PD-L1 Biomarker Testing by Company Type (Tier 1, Tier 2, and Tier 3)
Table 58. Market Position of Players in PD-L1 Biomarker Testing, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 59. Head Office of Key PD-L1 Biomarker Testing Players
Table 60. PD-L1 Biomarker Testing Market: Company Product Type Footprint
Table 61. PD-L1 Biomarker Testing Market: Company Product Application Footprint
Table 62. PD-L1 Biomarker Testing New Market Entrants and Barriers to Market Entry
Table 63. PD-L1 Biomarker Testing Mergers, Acquisition, Agreements, and Collaborations
Table 64. Global PD-L1 Biomarker Testing Consumption Value (USD Million) by Type (2018-2023)
Table 65. Global PD-L1 Biomarker Testing Consumption Value Share by Type (2018-2023)
Table 66. Global PD-L1 Biomarker Testing Consumption Value Forecast by Type (2024-2029)
Table 67. Global PD-L1 Biomarker Testing Consumption Value by Application (2018-2023)
Table 68. Global PD-L1 Biomarker Testing Consumption Value Forecast by Application (2024-2029)
Table 69. North America PD-L1 Biomarker Testing Consumption Value by Type (2018-2023) & (USD Million)
Table 70. North America PD-L1 Biomarker Testing Consumption Value by Type (2024-2029) & (USD Million)
Table 71. North America PD-L1 Biomarker Testing Consumption Value by Application (2018-2023) & (USD Million)
Table 72. North America PD-L1 Biomarker Testing Consumption Value by Application (2024-2029) & (USD Million)
Table 73. North America PD-L1 Biomarker Testing Consumption Value by Country (2018-2023) & (USD Million)
Table 74. North America PD-L1 Biomarker Testing Consumption Value by Country (2024-2029) & (USD Million)
Table 75. Europe PD-L1 Biomarker Testing Consumption Value by Type (2018-2023) & (USD Million)
Table 76. Europe PD-L1 Biomarker Testing Consumption Value by Type (2024-2029) & (USD Million)
Table 77. Europe PD-L1 Biomarker Testing Consumption Value by Application (2018-2023) & (USD Million)
Table 78. Europe PD-L1 Biomarker Testing Consumption Value by Application (2024-2029) & (USD Million)
Table 79. Europe PD-L1 Biomarker Testing Consumption Value by Country (2018-2023) & (USD Million)
Table 80. Europe PD-L1 Biomarker Testing Consumption Value by Country (2024-2029) & (USD Million)
Table 81. Asia-Pacific PD-L1 Biomarker Testing Consumption Value by Type (2018-2023) & (USD Million)
Table 82. Asia-Pacific PD-L1 Biomarker Testing Consumption Value by Type (2024-2029) & (USD Million)
Table 83. Asia-Pacific PD-L1 Biomarker Testing Consumption Value by Application (2018-2023) & (USD Million)
Table 84. Asia-Pacific PD-L1 Biomarker Testing Consumption Value by Application (2024-2029) & (USD Million)
Table 85. Asia-Pacific PD-L1 Biomarker Testing Consumption Value by Region (2018-2023) & (USD Million)
Table 86. Asia-Pacific PD-L1 Biomarker Testing Consumption Value by Region (2024-2029) & (USD Million)
Table 87. South America PD-L1 Biomarker Testing Consumption Value by Type (2018-2023) & (USD Million)
Table 88. South America PD-L1 Biomarker Testing Consumption Value by Type (2024-2029) & (USD Million)
Table 89. South America PD-L1 Biomarker Testing Consumption Value by Application (2018-2023) & (USD Million)
Table 90. South America PD-L1 Biomarker Testing Consumption Value by Application (2024-2029) & (USD Million)
Table 91. South America PD-L1 Biomarker Testing Consumption Value by Country (2018-2023) & (USD Million)
Table 92. South America PD-L1 Biomarker Testing Consumption Value by Country (2024-2029) & (USD Million)
Table 93. Middle East & Africa PD-L1 Biomarker Testing Consumption Value by Type (2018-2023) & (USD Million)
Table 94. Middle East & Africa PD-L1 Biomarker Testing Consumption Value by Type (2024-2029) & (USD Million)
Table 95. Middle East & Africa PD-L1 Biomarker Testing Consumption Value by Application (2018-2023) & (USD Million)
Table 96. Middle East & Africa PD-L1 Biomarker Testing Consumption Value by Application (2024-2029) & (USD Million)
Table 97. Middle East & Africa PD-L1 Biomarker Testing Consumption Value by Country (2018-2023) & (USD Million)
Table 98. Middle East & Africa PD-L1 Biomarker Testing Consumption Value by Country (2024-2029) & (USD Million)
Table 99. PD-L1 Biomarker Testing Raw Material
Table 100. Key Suppliers of PD-L1 Biomarker Testing Raw Materials
List of Figures
Figure 1. PD-L1 Biomarker Testing Picture
Figure 2. Global PD-L1 Biomarker Testing Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global PD-L1 Biomarker Testing Consumption Value Market Share by Type in 2022
Figure 4. PD-L1 (22C3)
Figure 5. PD-L1(28-8)
Figure 6. PD-L1 (SP142)
Figure 7. PD-L1 (SP263)
Figure 8. Other
Figure 9. Global PD-L1 Biomarker Testing Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 10. PD-L1 Biomarker Testing Consumption Value Market Share by Application in 2022
Figure 11. Hospital Picture
Figure 12. Diagnostic Center Picture
Figure 13. Others Picture
Figure 14. Global PD-L1 Biomarker Testing Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 15. Global PD-L1 Biomarker Testing Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 16. Global Market PD-L1 Biomarker Testing Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 17. Global PD-L1 Biomarker Testing Consumption Value Market Share by Region (2018-2029)
Figure 18. Global PD-L1 Biomarker Testing Consumption Value Market Share by Region in 2022
Figure 19. North America PD-L1 Biomarker Testing Consumption Value (2018-2029) & (USD Million)
Figure 20. Europe PD-L1 Biomarker Testing Consumption Value (2018-2029) & (USD Million)
Figure 21. Asia-Pacific PD-L1 Biomarker Testing Consumption Value (2018-2029) & (USD Million)
Figure 22. South America PD-L1 Biomarker Testing Consumption Value (2018-2029) & (USD Million)
Figure 23. Middle East and Africa PD-L1 Biomarker Testing Consumption Value (2018-2029) & (USD Million)
Figure 24. Global PD-L1 Biomarker Testing Revenue Share by Players in 2022
Figure 25. PD-L1 Biomarker Testing Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 26. Global Top 3 Players PD-L1 Biomarker Testing Market Share in 2022
Figure 27. Global Top 6 Players PD-L1 Biomarker Testing Market Share in 2022
Figure 28. Global PD-L1 Biomarker Testing Consumption Value Share by Type (2018-2023)
Figure 29. Global PD-L1 Biomarker Testing Market Share Forecast by Type (2024-2029)
Figure 30. Global PD-L1 Biomarker Testing Consumption Value Share by Application (2018-2023)
Figure 31. Global PD-L1 Biomarker Testing Market Share Forecast by Application (2024-2029)
Figure 32. North America PD-L1 Biomarker Testing Consumption Value Market Share by Type (2018-2029)
Figure 33. North America PD-L1 Biomarker Testing Consumption Value Market Share by Application (2018-2029)
Figure 34. North America PD-L1 Biomarker Testing Consumption Value Market Share by Country (2018-2029)
Figure 35. United States PD-L1 Biomarker Testing Consumption Value (2018-2029) & (USD Million)
Figure 36. Canada PD-L1 Biomarker Testing Consumption Value (2018-2029) & (USD Million)
Figure 37. Mexico PD-L1 Biomarker Testing Consumption Value (2018-2029) & (USD Million)
Figure 38. Europe PD-L1 Biomarker Testing Consumption Value Market Share by Type (2018-2029)
Figure 39. Europe PD-L1 Biomarker Testing Consumption Value Market Share by Application (2018-2029)
Figure 40. Europe PD-L1 Biomarker Testing Consumption Value Market Share by Country (2018-2029)
Figure 41. Germany PD-L1 Biomarker Testing Consumption Value (2018-2029) & (USD Million)
Figure 42. France PD-L1 Biomarker Testing Consumption Value (2018-2029) & (USD Million)
Figure 43. United Kingdom PD-L1 Biomarker Testing Consumption Value (2018-2029) & (USD Million)
Figure 44. Russia PD-L1 Biomarker Testing Consumption Value (2018-2029) & (USD Million)
Figure 45. Italy PD-L1 Biomarker Testing Consumption Value (2018-2029) & (USD Million)
Figure 46. Asia-Pacific PD-L1 Biomarker Testing Consumption Value Market Share by Type (2018-2029)
Figure 47. Asia-Pacific PD-L1 Biomarker Testing Consumption Value Market Share by Application (2018-2029)
Figure 48. Asia-Pacific PD-L1 Biomarker Testing Consumption Value Market Share by Region (2018-2029)
Figure 49. China PD-L1 Biomarker Testing Consumption Value (2018-2029) & (USD Million)
Figure 50. Japan PD-L1 Biomarker Testing Consumption Value (2018-2029) & (USD Million)
Figure 51. South Korea PD-L1 Biomarker Testing Consumption Value (2018-2029) & (USD Million)
Figure 52. India PD-L1 Biomarker Testing Consumption Value (2018-2029) & (USD Million)
Figure 53. Southeast Asia PD-L1 Biomarker Testing Consumption Value (2018-2029) & (USD Million)
Figure 54. Australia PD-L1 Biomarker Testing Consumption Value (2018-2029) & (USD Million)
Figure 55. South America PD-L1 Biomarker Testing Consumption Value Market Share by Type (2018-2029)
Figure 56. South America PD-L1 Biomarker Testing Consumption Value Market Share by Application (2018-2029)
Figure 57. South America PD-L1 Biomarker Testing Consumption Value Market Share by Country (2018-2029)
Figure 58. Brazil PD-L1 Biomarker Testing Consumption Value (2018-2029) & (USD Million)
Figure 59. Argentina PD-L1 Biomarker Testing Consumption Value (2018-2029) & (USD Million)
Figure 60. Middle East and Africa PD-L1 Biomarker Testing Consumption Value Market Share by Type (2018-2029)
Figure 61. Middle East and Africa PD-L1 Biomarker Testing Consumption Value Market Share by Application (2018-2029)
Figure 62. Middle East and Africa PD-L1 Biomarker Testing Consumption Value Market Share by Country (2018-2029)
Figure 63. Turkey PD-L1 Biomarker Testing Consumption Value (2018-2029) & (USD Million)
Figure 64. Saudi Arabia PD-L1 Biomarker Testing Consumption Value (2018-2029) & (USD Million)
Figure 65. UAE PD-L1 Biomarker Testing Consumption Value (2018-2029) & (USD Million)
Figure 66. PD-L1 Biomarker Testing Market Drivers
Figure 67. PD-L1 Biomarker Testing Market Restraints
Figure 68. PD-L1 Biomarker Testing Market Trends
Figure 69. Porters Five Forces Analysis
Figure 70. Manufacturing Cost Structure Analysis of PD-L1 Biomarker Testing in 2022
Figure 71. Manufacturing Process Analysis of PD-L1 Biomarker Testing
Figure 72. PD-L1 Biomarker Testing Industrial Chain
Figure 73. Methodology
Figure 74. Research Process and Data Source
